Hello,

I exported svg from isodraw 7.1 and imported in editor 6.1. The pdf output does not come very well. If export the same image to eps it comes perfect.

I have attached screenshot and svg file

Can anyone help?

Thanks

Manoj

Background (Working with Arbortext 6.1 M030 w/Print Composer for PDFs and Mil-Std 40051-2B DTD-Stylesheets)

Since the latest US Army LOGSA update round to Version 5.0, it seems that the Abortext ''New Page' command ( <?Pub _newpage?> ) either no longer works or is severely curtailed. We typically used this command in the past, to help format content somewhat, as the LOGSA DTD / Stylesheet combo produces a pretty abysmal output to PDF using Print Composer.

However, in the latest interation, the PDFs look really awful (pages break wherever, in between warning icons and warning text, between figures and the preceding steps, with no rhyme nor reason to content organization, hierarchy, dependency, or even Mazlov's hierarchy of needs.... (just checking).

Questions:

1. I'm looking for a way to 'right the ship' and get back to providing quality PDF (deliverable requirement) back to the soldiers. Anyone else experiencing (or have experienced) this and has any thoughts or suggestions?

2. Does the print server version (instead of Print Composer) do this too with Mil-Std 40051-2B and Arbortext 6.1? Or is this just a 'feature' for small shops and Print Composer only PDF-ing?

3. Is there a (not too convoluted - temporary) way to delve into the stylesheet files, and prevent the stylesheet from ignoring the <?Pub _newpage?> ?

Any/all thoughts, insights or suggestions greatly appreciated. Thanks for reading.

Regards all,

Bob Williams

Bristol RI

Hello gurus!!

I'm having an issue with one of my implementations in the Arbortext Editor, as you might see, I'm receiving the message from the image I'm attaching, does anybody know how  to manage virtual memory space in the editor? Is that possible?

In advance I appreciate your time and help.

Paulette Z.

Hi All,

I need to change the newline processing instruction markup. Has anyone done this before ?

Kind Regards

Ashona

  Hi,

  Plan to migrate the below  Documentum  Components for
new wisdom 2016 project.

1. WebTop    -  6.7 SP2   to  6.8  version
2. Content Server     -  6.7 SP1   to  D7.2 SP2 version
3. DFS  - 6.7 SP1   to  D7.2 SP2 version
4. Windows OS      -  2008  to  2012

Can you please check Arbortext Editor and Arbortext Engine  current version (6.0M060 ) or new version (6.1 or if any) Compatibility  with  WebTop and content server  above mention
new version and provide the details on this.

Thanks for helping  on this .

Regards

Siva

I currently have a FOSI that is failing to compile/print most of the times (but not all of the time).

In the "formatter messages" window, the warning is "An empty page fault occurred."

In the event log, the warning is "Error: Failure post-processing for composer type pdf.  FATAL ERROR: Operation terminated."

and

"ERROR: Runtime error formatting document: main:: Error='[A12627] Error: A fatal formatting error occurred.  Refer to the formatting faults log file "file name here"."

The log file has been of no help.  I am unable to consistently get this FOSI to compile or fail at the same elements or point in processing, nor does it repeat with any other FOSI.

Any ideas?

Can any one suggest how to do a program or set of instruction (like macro) which will show the errors in the authoring file (content) on running the program.

Eg: The statement should be

Correct: “put the unit in position”

Wrong:  “put the unit in its position”

If we use in its position in the authoring, it should show error

I know you can highlight it and choose edit, fit elements. This will center it but it will scale it to fit the square. Is there an automatic way to center the object on the page without scaling it?

Hello everyone,

Have you seen any issues with Drag and Drop in Arbortext Editor 7?  We're seeing behavior where selected text jumps to the middle of the screen when trying to drag it to a new location.  This is most obvious in tables, but also occurs with other tags.  I haven't found any sort of advanced preference that would control something like this.  Deleting the preferences file does not help.

This issue is particularly noticeable when selecting text towards the bottom of the Arbortext window and trying to drag it to the top part of the window, especially when a table takes up the entire window.  As soon as I begin to move the text, the file window scrolls so the selected text is suddenly relocated vertically to the middle of the screen.  This does not occur in Arbortext 5.4, and I don't know about Arbortext 6 behavior.

Have any of you seen this and know how to resolve it? 

Thanks!

>> Randy

<?xml version="1.0" encoding="UTF-8"?>

<!DOCTYPE StandardLetterBody PUBLIC "-//Aventis Pharmaceuticals//Standard Letter Body//EN" "file:C:\Users\NM28079\medinfo\XML_Standard_Letter_Body\StandardLetterBody.dtd">

<StandardLetterBody xmlns:slb="http://www.aventis.com/amis/standardletterbody" xmlns:atict="http://www.arbortext.com/namespace/atict"><atict:info color="" print="" ref="0" tracking="off"/><atict:user fullname="Bell, Mark" user="nm60913"/>

<slb:DocumentProperties>

<DocumentTitle>Intracellular Concentration</DocumentTitle>

<TherapeuticArea>Respiratory</TherapeuticArea>

<GenericName>telithromycin</GenericName>

<TradeName>Ketek</TradeName>

<DocumentSubject>Pharmacokinetics-Pharmacodynamics</DocumentSubject>

<SubjectCategory/>

<SubjectSubCategory/>

<ChangeSummary>Final, added Barcia-Macay reference</ChangeSummary>

</slb:DocumentProperties>

<slb:DocumentContent>

<sect1>

<title>As stated in the KETEK package insert:<ref:reference confidentiality="Public" object_id="09012bda8001f259" xmlns:ref="ref"><ref:packageinsert><ref:tradename>Ketek</ref:tradename><ref:companylocation>Bridgewater, NJ</ref:companylocation><ref:companyname>sanofi-aventis U.S.</ref:companyname><ref:publicationdate>2010</ref:publicationdate></ref:packageinsert></ref:reference></title>

<blockquote>

<para><emphasis role="bold">CLINICAL PHARMACOLOGY</emphasis></para>

<para><emphasis role="bold"><emphasis role="underline">Pharmacokinetics</emphasis></emphasis></para>

<para><emphasis role="bold">Distribution:</emphasis></para>

<para>Telithromycin concentrations in ...alveolar macrophages after

800 mg once daily dosing for 5 days in patients are displayedin Table

2.</para>

<informaltable>

<tgroup cols="5">

<?PubTbl tgroup dispwid="6.64in"?>

<colspec colname="col1" colwidth="1.60*"/><colspec colname="col2" colwidth="0.85*"/><colspec colname="col3" colwidth="0.77*"/><colspec colname="col4" colwidth="0.84*"/><colspec colname="col5" colwidth="0.97*"/>

<tbody>

<row>

<entry nameend="col5" namest="col1" rowsep="0"><emphasis role="bold">Table 2</emphasis></entry>

</row>

<row>

<entry colsep="0" nameend="col2" namest="col1"><emphasis role="bold"/></entry>

<entry colsep="1" nameend="col5" namest="col3">Mean concentration

(µg/mL)</entry>

</row>

<row>

<entry/>

<entry><para><emphasis role="bold">Hours</emphasis><?Pub _newline

?><emphasis role="bold">post-</emphasis><?Pub _newline?><emphasis role="bold">dose</emphasis></para></entry>

<entry valign="bottom"><para><emphasis role="bold">Tissue or</emphasis><?Pub _newline?><emphasis role="bold">fluid</emphasis></para></entry>

<entry valign="bottom"><para><emphasis role="bold">Plasma</emphasis></para></entry>

<entry><para><emphasis role="bold">Tissue/</emphasis><?Pub _newline

?><emphasis role="bold">Plasma</emphasis><?Pub _newline?><emphasis role="bold">Ratio</emphasis></para></entry>

</row>

<row>

<entry>Alveolar macrophages</entry>

<entry align="center"><para>2<?Pub _newline?>8<?Pub _newline?>24</para></entry>

<entry align="center"><para>65<?Pub _newline?>100<?Pub _newline?>41</para></entry>

<entry align="center"><para>1.07<?Pub _newline?>0.605<?Pub _newline

?>0.073</para></entry>

<entry align="center"><para>55<?Pub _newline?>180<?Pub _newline?>540</para></entry>

</row>

</tbody>

</tgroup>

</informaltable>

<para>Telithromycin concentration in white blood cells exceeds the

concentration in plasma and is eliminated more slowly from white blood

cells than from plasma. Mean white blood cell concentrations of telithromycin

peaked at 72.1 µg/mL at 6 hours, and remained at 14.1 µg/mL

24 hours after 5 days of repeated dosing of 600 mg once daily. After

10 days, repeated dosing of 600 mg once daily, white blood cell concentrations

remained at 8.9 µg/mL 48 hours after the last dose.</para>

<para><emphasis role="underline"><emphasis role="bold">Microbiology</emphasis></emphasis></para>

<para>...Telithromycin concentrates in phagocytes where it exhibits

activity against intracellular respiratory pathogens...</para>

</blockquote>

<para>Telithromycin, a ketolide<ref:reference confidentiality="Public" object_id="09012bda8001b69f" xmlns:ref="ref"><ref:journalarticle><ref:author>Blaney SM</ref:author><ref:author>Seibel NL</ref:author><ref:author>O'Brien M</ref:author><ref:author>Reaman GH</ref:author><ref:author>Berg SL</ref:author><ref:author>Adamson PC</ref:author><ref:author>Poplack DG</ref:author><ref:author>Krailo MD</ref:author><ref:author>Mosher R</ref:author><ref:author>Balis FM</ref:author><ref:journaltitle>Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors:  a collaborative Pediatric Branch, National Cancer Institute and Children's Cancer Group trial</ref:journaltitle><ref:serialtitle>J Clin Oncol</ref:serialtitle><ref:publicationdate>1997</ref:publicationdate><ref:volume>15</ref:volume><ref:issuenumber>4</ref:issuenumber><ref:firstpage>1538</ref:firstpage><ref:lastpage>1543</ref:lastpage></ref:journalarticle></ref:reference> having a keto-group rather than

a sugar (L-cladinose) at position 3 of the lactone ring, is a derivative

of the macrolide antibiotics.  Macrolide antibiotics concentrate within

host cells, a characteristic responsible for activity against intracellular

pathogens and modulation of cell metabolism and function.<ref:reference confidentiality="Public" object_id="09012bda8001f8af" xmlns:ref="ref"><ref:journalarticle><ref:author>Labro MT</ref:author><ref:author>Abdelghaffar H</ref:author><ref:journaltitle>Immunomodulation by macrolide antibiotics</ref:journaltitle><ref:serialtitle>J Chemother</ref:serialtitle><ref:publicationdate>2001</ref:publicationdate><ref:volume>13</ref:volume><ref:issuenumber>1</ref:issuenumber><ref:firstpage>3</ref:firstpage><ref:lastpage>8</ref:lastpage></ref:journalarticle></ref:reference>  Telithromycin

has been documented to accumulate within various cells.<ref:reference confidentiality="Confidential" object_id="09012bda8001f3fa" xmlns:ref="ref"><ref:studyreport><ref:studyreportnumber>NDA 21-144 Original</ref:studyreportnumber></ref:studyreport></ref:reference> <hiddentext xmlns:ref="ref">(NDA Section 7.B.1.2.5.4, 7:v001:p172–176)</hiddentext>  At an extracellular concentration of 2.5 µg/mL, telithromycin

gradually accumulates in polymorphonuclear neutrophils (PMNs) with

an intracellular/extracellular concentration ratio (C/E) ranging from

27.0 ± 8.1 (at 5 minutes) to 348 ± 27.1 (at 160 minutes).

At an extracellular concentration of 2 µg/mL, telithromycin

uptake into macrophages is also rapid with a C/E ratio of 65 (at 60

minutes).  </para><?Pub Caret 25?>

</sect1>

<sect1>

<title>Intracellular Kinetics of Telithromycin</title>

<para>The ability of telithromycin to enter PMNs, peripheral blood

mononuclear cells and cells of hematopoietic and nonhematopoietic

origin was investigated <emphasis role="italic">in vitro</emphasis>.<ref:reference confidentiality="Public" object_id="09012bda8001f8b1" xmlns:ref="ref"><ref:journalarticle><ref:author>Miossec-Bartoli C</ref:author><ref:author>Pilatre L</ref:author><ref:author>Peyron P</ref:author><ref:author>N'Diaye EN</ref:author><ref:author>Collart-Dutilleul V</ref:author><ref:author>Maridonneau-Parini I</ref:author><ref:author>Diu-Hercend A</ref:author><ref:journaltitle>The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells.</ref:journaltitle><ref:serialtitle>Antimicrob Agents Chemother</ref:serialtitle><ref:publicationdate>1999</ref:publicationdate><ref:volume>43</ref:volume><ref:issuenumber>10</ref:issuenumber><ref:firstpage>2457</ref:firstpage><ref:lastpage>2462</ref:lastpage></ref:journalarticle></ref:reference> Telithromycin was slowly taken up into PMNs achieving a C/E concentration

ratio around 300 after 2 hours. It concentrated and remained within

the cells, with 80% of the drug remaining cell associated after 2

hours.  Subcellular fractionation of the PMNs showed that the majority

of telithromycin resides within the azurophil granules.  Incorporation

of telithromycin into other cell types (peripheral blood mononuclear

cells, T-lymphocytic cells, monocytic cells, erythroid progenitor

cell types, promyelocytic cell line and colon carcinoma cell line)

was poor with quick release.</para>

<para>In order for an antimicrobial agent to be effectively transported

to a location of infection, it must not interfere with the ability

of the neutrophil to sense chemoattractants and to move normally.

A study was performed to evaluate the effect of telithromycin on

these properties in an <emphasis role="italic">in vitro</emphasis> model utilizing <emphasis role="italic">Streptococcus pyogenes</emphasis>, <emphasis role="italic">Staphylococcus aureus</emphasis>, <emphasis role="italic">Escherichia coli</emphasis>, and <emphasis role="italic">Micrococcus luteus</emphasis>.<ref:reference confidentiality="Public" object_id="09012bda8001f8b3" xmlns:ref="ref"><ref:journalarticle><ref:author>Mandell GL</ref:author><ref:author>Coleman E</ref:author><ref:journaltitle>Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils.</ref:journaltitle><ref:serialtitle>Antimicrob Agents Chemother</ref:serialtitle><ref:publicationdate>2001</ref:publicationdate><ref:volume>45</ref:volume><ref:issuenumber>6</ref:issuenumber><ref:firstpage>1794</ref:firstpage><ref:lastpage>1798</ref:lastpage></ref:journalarticle></ref:reference>  Among the agents tested (penicillin G, azithromycin, ciprofloxacin,

levofloxacin, and moxifloxacin), telithromycin was documented to be

highly concentrated and slowly released from PMNs.  Telithromycin

was transported by PMNs towards a chemoattractant, resulting in zones

of bacterial inhibition that were greater than those reported for

the other agents tested. </para>

<para>The intracellular kinetics of telithromycin, its effects on

pro-inflammatory cytokines, and its effect on PMN bactericidal activity

was examined in a series of<emphasis role="italic"> in vitro</emphasis> studies. Telithromycin was shown to concentrate in PMNs displaying

a C/E concentration ratio of 31 ± 4.2 at 5 minutes up to 348

± 27.1 at 180 minutes.<ref:reference confidentiality="Public" object_id="09012bda8001f81c" xmlns:ref="ref"><ref:journalarticle><ref:author>Vazifeh D</ref:author><ref:author>Preira A</ref:author><ref:author>Bryskier A</ref:author><ref:author>Labro MT</ref:author><ref:journaltitle>Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils</ref:journaltitle><ref:serialtitle>Antimicrob Agents Chemother</ref:serialtitle><ref:publicationdate>1998</ref:publicationdate><ref:volume>42</ref:volume><ref:issuenumber>8</ref:issuenumber><ref:firstpage>1944</ref:firstpage><ref:lastpage>1951</ref:lastpage></ref:journalarticle></ref:reference> It was noted

that approximately 60% of telithromycin was concentrated in the granular

compartment of PMNs and the intracellular uptake displayed Michaelis-Menten

saturation kinetics.  Uptake was dependent on environmental temperatures

and extracellular calcium was necessary for optimal uptake.  Telithromycin

weakly triggered granule exocytosis from PMNs and inhibited superoxide

anion production (oxidative burst) in a time and concentration-dependent

manner. </para>

<para>The effects of various proinflammatory cytokines (interleukin

1 [IL-1], IL-6, IL-8, gamma interferon, tumor necrosis factor alpha

(TNF-a) and granulocyte-macrophage colony stimulating factor (GM-CSF)

on cellular uptake of telithromycin and the interaction of telithromycin

with polymorphonuclear neutrophils (PMN) has been investigated.<ref:reference confidentiality="Public" object_id="09012bda8001bcf7" xmlns:ref="ref"><ref:journalarticle><ref:author>Vazifeh D</ref:author><ref:author>Bryskier A</ref:author><ref:author>Labro MT</ref:author><ref:journaltitle>Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils</ref:journaltitle><ref:serialtitle>Antimicrob Agents Chemother</ref:serialtitle><ref:publicationdate>2000</ref:publicationdate><ref:volume>44</ref:volume><ref:issuenumber>3</ref:issuenumber><ref:firstpage>511</ref:firstpage><ref:lastpage>521</ref:lastpage></ref:journalarticle></ref:reference>  In this study, TNF-a and GM-CSF were the only cytokines to exert

an effect on telithromycin, lessening the inhibitory effects of telithromycin

on PMN oxidant production.  Inhibitory concentrations suggest that

telithromycin acts downstream of the priming effect of TNF-a and GM-CSF.

TNF-a and GM-CSF also modestly decreased the PMN uptake of telithromycin

by approximately 20%.</para>

<para>In the final study, the effects of telithromycin on bactericidal

activity of PMNs was studied utilizing four strains of Staphylococcus

aureus with different profiles of susceptibility to macrolides and

ketolides.<ref:reference confidentiality="Public" object_id="09012bda8001f8b5" xmlns:ref="ref"><ref:journalarticle><ref:author>Vazifeh D</ref:author><ref:author>Abdelghaffar H</ref:author><ref:author>Labro MT</ref:author><ref:journaltitle>Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin.</ref:journaltitle><ref:serialtitle>Antimicrob Agents Chemother</ref:serialtitle><ref:publicationdate>2002</ref:publicationdate><ref:volume>46</ref:volume><ref:issuenumber>5</ref:issuenumber><ref:firstpage>1364</ref:firstpage><ref:lastpage>1374</ref:lastpage><ref:url>www.ggggle.com</ref:url></ref:journalarticle></ref:reference>  The effects of intracellular bacteria on cellular uptake of telithromycin

was also evaluated.  High concentrations of telithromycin, which abolished

the oxidative metabolism of the PMNs, did not impair bactericidal

function.  In a global assay, the bactericidal activity of telithromycin

was not impaired in the presence of PMNs.  The authors concluded that

the antibacterial activity of telithromycin against <emphasis role="italic" xmlns:ref="ref">S. aureus</emphasis> in this setting

was a direct effect of the drug, and not due to a synergistic interaction

with the bactericidal system of the PMNs. </para>

<para>The activity of telithromycin against intracellular <emphasis role="italic">Legionella pneumophilia</emphasis> was investigated

in an <emphasis role="italic">in vitro</emphasis> study using human

monocytes.<ref:reference confidentiality="Public" object_id="09012bda8001f8b6" xmlns:ref="ref"><ref:journalarticle><ref:author>Baltch AL</ref:author><ref:author>Smith RP</ref:author><ref:author>Ritz WJ</ref:author><ref:author>Franke MA</ref:author><ref:author>Michelsen PB</ref:author><ref:journaltitle>Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila.</ref:journaltitle><ref:serialtitle>J Antimicrob Chemother</ref:serialtitle><ref:publicationdate>2000</ref:publicationdate><ref:volume>46</ref:volume><ref:issuenumber>1</ref:issuenumber><ref:firstpage>51</ref:firstpage><ref:lastpage>55</ref:lastpage></ref:journalarticle></ref:reference> Telithromycin (10X MIC for 4 days) produced a significant antimicrobial

effect on monocytes exposed to <emphasis role="italic" xmlns:ref="ref">L. pneumophlia</emphasis>.  There were no significant differences

observed with regards to the growth of intracellular <emphasis role="italic" xmlns:ref="ref">L. pneumophilia</emphasis> on days 2-4

when telithromycin was removed following 1 day of exposure.  The authors

noted that removal of telithromycin did not affect the continued antimicrobial

activity of the monocytes. </para>

<para>Telithromycin's intracellular activity against <emphasis role="italic">S. aureus </emphasis> ATCC 25493 (MIC 2 mg/L) was evaluated

in human THP-1 macrophages infection model.<ref:reference confidentiality="Public" object_id="09012bda80020c90" xmlns:ref="ref"><ref:abstract><ref:author>Barcia-Macay M</ref:author><ref:author>Seral C</ref:author><ref:author>Mingeot-Leclercq MP</ref:author><ref:author>Tulkens PM</ref:author><ref:abstracttitle>Comparative activity of 12 antibiotics (ABs) used at clinically-meaningful extracellular concentration against S. aureus in broth and in human THP-1 macrophages</ref:abstracttitle><ref:conference>43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003</ref:conference><ref:abstractnumber>A-1174</ref:abstractnumber></ref:abstract></ref:reference> At a concentration of 2 mg/L, telithromycin's

extracellular and intracellular activities were -1.84±0.02

log change in cfu in 24 hours in broth and –1.14±0.04

log change in cfu in 24 hours in human THP-1 macrophages, respectively.</para>

<para>A study evaluated the effect of P-glycoprotein inhibitors (cyclosporin

A, verapamil, GF120918) on the accumulation and efflux of telithromycin

in J774 murine macrophages.<ref:reference confidentiality="Public" object_id="09012bda8001fd82" xmlns:ref="ref"><ref:journalarticle><ref:author>Seral C</ref:author><ref:author>Michot J-M</ref:author><ref:author>Chanteux H</ref:author><ref:author>Mingeot-Leclercq M-P</ref:author><ref:author>Tulkens PM</ref:author><ref:author>Van Bambeke F</ref:author><ref:journaltitle>Influence of p-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages</ref:journaltitle><ref:serialtitle>Antimicrob Agents Chemother</ref:serialtitle><ref:publicationdate>2003</ref:publicationdate><ref:volume>47</ref:volume><ref:issuenumber>3</ref:issuenumber><ref:firstpage>1047</ref:firstpage><ref:lastpage>1051</ref:lastpage></ref:journalarticle></ref:reference> In the presence of the inhibitors, there was a 2– to 3.5–fold

increase in the rate of telithromycin accumulation in the macrophages;

however, the efflux of telithromycin from the macrophages was slowed

marginally. Cyclosporin and GF120918 increased the accumulation of

telithromycin in the macrophages by 3– to 4–fold following

3 hours of cell incubation with extracellular telithromycin (5 mg/L).

The effect of verapamil on telithromycin was lower than the effect

of the other inhibitors (P &lt; 0.05). The authors concluded that

the data strongly suggests that modulation of P-glycoprotein is responsible

for the observed effects on the accumulation of telithromycin. They

stated that the conclusions for the study were limited to J774 murine

macrophages and could not be applied to other phagocytic cells. The

effects of the efflux proteins on the intracellular activity of telithromycin

may need to be studied systematically.</para>

</sect1>

<sect1>

<title>Penetration of Telithromycin into WBCs and Alveolar Macrophages</title>

<para>The intracellular accumulation and concentration of telithromycin

in white blood cells (WBC) was studied in blood samples obtained from

healthy male volunteers.<ref:reference confidentiality="Public" object_id="09012bda8001f808" xmlns:ref="ref"><ref:poster><ref:author>Gia HP</ref:author><ref:author>Roeder V</ref:author><ref:author>Namour F</ref:author><ref:author>Sultan E</ref:author><ref:author>Lenfant B</ref:author><ref:postertitle>Telithromycin (HMR 3647) achieves high and sustained concentrations in white blood cells in man</ref:postertitle><ref:conference>5th International Conference on Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones, Seville, Spain, January 26-28, 2000</ref:conference><ref:posternumber>09.27</ref:posternumber></ref:poster></ref:reference> Following administration of either a

single oral dose of telithromycin 600 mg or the same dose administered

once daily for 10 days, WBC and plasma concentrations of telithromycin

as well as the WBC concentration/plasma concentration ratio and area

under the concentration-time curve (AUC) in WBCs and plasma were assessed.

It was reported that telithromycin rapidly concentrates in WBCs following

a single oral dose, reaching 44-fold greater levels than in plasma

1 hour after dosing and increasing to 705 at 24 hours post-dose.

The WBC/plasma concentration ratio ranged from 87 at 2 hours post-dose

on Day 5 to 2201 at 48 hours post-dose on Day 10.  The ratio of the

AUC (0-24 hours) for WBC to the AUC(0-24 hours) for plasma on Day

10 of the multiple dose study was 242.  The telithromycin concentration

in WBCs exceeded the minimum inhibitory concentration of respiratory

pathogens up to 48 hours following multiple dosing.  The authors concluded

that the data suggest a role for telithromycin against intracellular

pathogens.</para>

<para>The penetration of telithromycin into bronchopulmonary tissues

(alveolar macrophages (AM) and epithelial lining fluid (ELF)) was

evaluated in healthy male volunteers.<ref:reference confidentiality="Public" object_id="09012bda8001f7cc" xmlns:ref="ref"><ref:journalarticle><ref:author>Muller-Serieys C</ref:author><ref:author>Soler P</ref:author><ref:author>Cantalloube C</ref:author><ref:author>Lemaitre F</ref:author><ref:author>Gia HP</ref:author><ref:author>Brunner F</ref:author><ref:author>Andremont A</ref:author><ref:journaltitle>Bronchpulmonary disposition of the ketolide telithromycin (HMR 3647)</ref:journaltitle><ref:serialtitle>Antimicrob Agents Chemother</ref:serialtitle><ref:publicationdate>2001</ref:publicationdate><ref:volume>45</ref:volume><ref:issuenumber>11</ref:issuenumber><ref:firstpage>3104</ref:firstpage><ref:lastpage>3108</ref:lastpage></ref:journalarticle></ref:reference>  Following a 5–day course of oral telithromycin 800 mg once

daily, patients underwent fiberoptic bronchoscopy and bronchoalveolar

lavage at 2, 8, 24, or 48 hours.  Concentrations of telithromycin

in both AM and ELF were significantly greater than those in plasma

at each time point (P&lt;0.05).  Telithromycin was retained in AM

24 hours after dosing and was quantifiable 48 hours after dosing.

The authors concluded that while the data were obtained from noninfected

subjects, it was unlikely that infection would reduce the concentration

of telithromycin in AM and ELF.</para>

<para>In a study of 20 patients undergoing elective bronchoscopy,

the mean concentration of telithromycin in alveolar macrophages (AM),

epithelial lining fluid (ELF), and bronchial mucosal (BM) were measured

2, 12, and 24 hours after the last dose of a 5–day course of

oral telithromycin 800 mg once daily.<ref:reference confidentiality="Public" object_id="09012bda8001b980" xmlns:ref="ref"><ref:journalarticle><ref:author>Khair OA</ref:author><ref:author>Andrews JM</ref:author><ref:author>Honeybourne D</ref:author><ref:author>Jevons G</ref:author><ref:author>Vacheron F</ref:author><ref:author>Wise R</ref:author><ref:journaltitle>Lung concentrations of telithromycin after oral dosing</ref:journaltitle><ref:serialtitle>J Antimicrob Chemother</ref:serialtitle><ref:publicationdate>2001</ref:publicationdate><ref:volume>47</ref:volume><ref:issuenumber>6</ref:issuenumber><ref:firstpage>837</ref:firstpage><ref:lastpage>840</ref:lastpage></ref:journalarticle></ref:reference>  Telithromycin concentrations

in AM, ELF, and BM were higher (161.57 mg/L, 0.97 mg/L, and 0.78 mg/L,

respectively) than the plasma concentration (0.08 mg/L) at 24 hours

post-dose. At 24 hours post dose, the concentration of telithromycin

in BM and ELF was greater than the MIC90 for the common respiratory

pathogens, <emphasis role="italic" xmlns:ref="ref">Streptococcus pneumoniae</emphasis> (0.12 mg/L) and <emphasis role="italic" xmlns:ref="ref">Moraxella

catarrhalis</emphasis> (0.03 mg/L) as well as the atypical pathogen <emphasis role="italic" xmlns:ref="ref">Mycoplasma pneumoniae</emphasis> (0.001

mg/L). The telithromycin concentration in BM and ELF exceeded the

MIC90 for <emphasis role="italic" xmlns:ref="ref">Haemophilus influenzae</emphasis> (2 mg/L) for 12 hours.</para>

</sect1>

</slb:DocumentContent>

<slb:SupportMaterial>

<EnclosureList><enc:reference confidentiality="Public" object_id="09012bda8001f259" xmlns:enc="enc"><enc:packageinsert><enc:tradename>Ketek</enc:tradename><enc:companylocation>Bridgewater, NJ</enc:companylocation><enc:companyname>sanofi-aventis U.S.</enc:companyname><enc:publicationdate>2010</enc:publicationdate></enc:packageinsert></enc:reference></EnclosureList>

<EnclosureListPlaceHolder/>

<ReferenceListPlaceHolder/><AddReferenceList/>

<AddReferenceListPlaceHolder/></slb:SupportMaterial>

</StandardLetterBody><?Pub *0000024884?>

Hello Users!

We need your input.

We have started looking into upgrading the version of Perl that we ship with APP to 5.20, which is the latest stable version we can use without a huge amount of work. However, we have uncovered some unexpected problems including that the newer version of Perl, once integrated into APP, will not be compatible with ActiveState.

Some things to consider:

• We (PTC) have never ‘officially’ supported the use of ActiveState with APP.
• The newer version of Perl may be quicker (no guarantees, but some people have reported performance improvements in some use cases).
• The newer version of Perl will differ from the older version, so some testing by you will be necessary and perhaps changes needed to your Perl scripts.

So, my question to you all is: Do you want us to go ahead with the upgrade or not? Our inclination at the moment is not…

Please let me know either through the user group (or directly if you’d rather).

Thanks!

Simon

We would like to ask about the hardware & software requirements for the "Advanced Print Publisher win32 11.1".

Thank you in advance

Lipiatos Alexandros

Hi, I was recently updated from IsoDraw 7.1 to  7.3.  I am no longer able to import IGES files from PTC Creo Parametric into the updated version on IsoDraw. Previously I would "save as" out of PTC with Surfaces selected in the Export IGES Geometry.  I was able to open that into IsoDraw 7.1 fine.  Now when I choose the same selection in IsoDraw 7.3 nothing appears when I open that file in IsoDraw, it is a blank screen.  When I export with Wireframe edges selected I am able to get that file to open in IsoDraw however it is unusable. Has anyone experienced the same issue?

I have also noticed that several of the 3D tool options are missing from the tool bar, such as wireframe, HLR, Rendering, 3D select axis, etc. Those were all tools that I used. With 7.3 my tool list now displays with a 3D with a lock on it.  What does that mean?

I would appreciate any suggestions you may have. Thanks for your time.

Just wondering, have a guy working on some S1000D screen FOSIs, but not being a FOSI guy or having ready access to styler, is there a way to open, for instance, the crewSchema.xsd as a doctype, and allow for opening a test doc to use the FOSI panels?

Been goofing with directory structures, URI catalog entries, the closest I can get is doc arch will open the crewSchema without error, but errors when trying to open a test doc.

Is this just a limitation of doc arch, or is there another way?

thanks,

-Jason

Hello - The question I have deals with error detection within Arbortext.  Background:  I work in a group of 6 engineers that write service documentation using the SGML verion of Arbortext. This group includes a single book-boss, who is the most expert in SGML editor tools, including Arbortext.

I typically work on small books (100 - 200 pages) that are combined into larger books that amount to in excess of 4,000 pages.  When the junior writers submit smaller files (IDE) to the book-boss, one task performed by the book-boss is to remove formatting problems and things that might cause problems with the book to build without error.  I recently submitted a small book (<100 pages) IDE file to the book boss that had a syntax error that was not detectable using the "Completeness Check" or "Green Checkmark" or the publishing tool used to build.

It was discovered after three days of debugging at the larger book level (>4,000 pages) that the error I introduced was an extraneous "newline" command at the end of an ordered list (within a proper division).  In this case, nothing was entered after the "newline" command, so essentially a "newline" to nothing was the issue.  With the small book (<100 pages) there was no indication whatsoever an error existed. Several attempts to break the 4,000 page book up into smaller 1,000 page books and publish indicated the same: No Error. However, when the larger book went to publish (a 2.5 hour build time, each time) a fatal error occurred.  The Arbortext tool didn't issue any clue or error description of the "newline" to nothing fatal error before or after the build.

The process to find the error was the fine tooth comb method that was trial and error as the culprit IDE file was initially unknown.  This process took roughly 3 days of the book-boss's time.

Question: Are there error detection tools within Arbortext besides Completeness Check (Green Checkmark) or the ultimate publish the book and hope for the best method.

Suggestion-Question: If not, is PTC working on improving error detection so that hidden errors in small books go detected early in the documentation process before they make it into the larger books, making it painstaking to resolve errors, in the case above, a minor syntax error.

Thank you, William Howell

Hi,

I am looking for a solution in Arbortext Isodraw 7.3, Currently i am using Arbortext Isodraw 7.3 to explode 3d models and converting it into 2d, the problem here is after converting the 3d model into 2d the elements are getting miss.For Example : The ellipse and the lines are not joining well. Pls see the attached file and kindly give me a positive reply of this question.

I know you can highlight it and choose edit, fit elements. This will center it but it will scale it to fit the square. Is there an automatic way to center the object on the page without scaling it?

We are looking into adding hot spots to our images used in our online parts catalog system. Currently we supply a third party with pdfs and they add hotspot info to the images they create from the pdfs. What sort of process is it to create hotspots for an illustration. We looked the PTC tutorial and all the parts are individiaul not grouped together. If you use hotspots can you still have your image linked back to the source? Our process curently is that we use jt files and place them onto the open idr file, explode and make it presentable, add callouts, export to CGM.

Any guidance would be appreciated.

Bryon

Can someone explain why a new option appears in the New Dialog when connected to Windchill? Can it be suppressed?

The Windchill instance is SIM 10.2 M030.

Thanks.